JUPITER NEUROSCIENCES, INC. Financing Cash Flow
JUPITER NEUROSCIENCES, INC. (JUNS) reported Financing Cash Flow of $1.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.45M.
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $5.51K.
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2024-12-31 was $7.47M, a 5642.34% increase year-over-year.
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2024-09-30 was $28.00K.
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2025 was $5.43M, a 28.99% decline from fiscal 2024.
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2024 was $7.65M, a 1619.56% increase from fiscal 2023.
- JUPITER NEUROSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2023 was $445.00K.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.46M 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | $5.51K 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $5.43M 10-K · filed 2026-04-01 | |||
| 2024-12-31 | $7.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $7.49M derived: sum of 2 quarters · filed 2026-04-01 | $7.61M derived: sum of 3 quarters · filed 2026-04-01 | $7.65M 10-K · filed 2026-04-01 |
| 2024-09-30 | $28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $142.00K derived: sum of 2 quarters · filed 2025-11-14 | $187.00K 10-Q · filed 2025-11-14 | $317.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $159.00K 10-Q · filed 2025-08-19 | $289.00K derived: sum of 3 quarters · filed 2025-08-19 | |
| 2024-03-31 | $45.00K 10-Q · filed 2025-05-15 | $175.00K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $445.00K 10-K · filed 2025-03-28 | ||
| 2023-09-30 | $315.00K 10-Q · filed 2024-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |